Cover Image
市場調查報告書

冠狀病毒感染疾病 : 開發平台分析

Coronavirus Infection - Pipeline Review, H1 2016

出版商 Global Markets Direct 商品編碼 302493
出版日期 內容資訊 英文 62 Pages
訂單完成後即時交付
價格
Back to Top
冠狀病毒感染疾病 : 開發平台分析 Coronavirus Infection - Pipeline Review, H1 2016
出版日期: 2016年03月22日 內容資訊: 英文 62 Pages
簡介

冠狀病毒是非常普遍的一種病毒,許多人都曾經感染過。感染人類冠狀病毒者,上呼吸道會有輕∼中度的疾病。冠狀病毒會藉由感染者對人的咳嗽、噴涕、私人接觸(接觸、握手等)傳染。主要症狀有鼻水噴涕、咳嗽、鼻塞、支氣管炎等。主要治療藥有抗病毒藥及止痛劑等。

本報告提供全球各國治療冠狀病毒感染疾病所用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

目錄

簡介

  • 分析範圍

冠狀病毒感染疾病概要

治療藥的開發

  • 冠狀病毒感染疾病開發中產品:概要
  • 冠狀病毒感染疾病開發中產品:比較分析

各企業開發中的冠狀病毒感染疾病治療藥

大學/研究機關研究中的冠狀病毒感染疾病治療藥

開發中產品的概要

  • 臨床階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

冠狀病毒感染疾病治療藥:開發中的產品一覽(各企業)

冠狀病毒感染疾病治療藥:研究中的產品一覽(大學/研究機關別)

冠狀病毒感染疾病開發治療藥的企業

  • AstraZeneca Plc
  • Hemispherx Biopharma, Inc.
  • Humabs BioMed SA
  • Inovio Pharmaceuticals, Inc.
  • NanoViricides, Inc.
  • Novavax, Inc.
  • Organic Vaccines
  • Phelix Therapeutics, LLC

冠狀病毒感染疾病:治療藥的評估

  • 單劑治療藥的情況
  • 並用治療藥的情況
  • 標的別
  • 各作用機制
  • 各投藥法
  • 各分子類型

藥物簡介

  • 冠狀病毒感染疾病細胞療法
    • 產品概要
    • 功能機制
    • 研究開發(R&D)的發展情形
  • 冠狀病毒·疫苗
  • 冠狀病毒感染疾病cathepsinL 抑制劑
  • FBR-001
  • INO-4500
  • 干擾素 α-n3
  • 干擾素 β-1a
  • LCA-60
  • MERS-COV
  • MERS-CoV Vaccine
  • 冠狀病毒感染疾病的單株抗體
  • 病毒感染小分子
  • SSYA-10001

冠狀病毒感染疾病治療藥:開發中產品的最新趨勢

冠狀病毒感染疾病治療藥:開發暫停的產品

冠狀病毒感染疾病相關產品的開發的里程碑

  • 值得注意的最新趨勢·新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC7738IDB

Summary

Global Markets Direct's, 'Coronavirus Infection - Pipeline Review, H1 2016', provides an overview of the Coronavirus Infection pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Coronavirus Infection, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Coronavirus Infection and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Coronavirus Infection
  • The report reviews pipeline therapeutics for Coronavirus Infection by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Coronavirus Infection therapeutics and enlists all their major and minor projects
  • The report assesses Coronavirus Infection therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Coronavirus Infection

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Coronavirus Infection
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Coronavirus Infection pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Coronavirus Infection Overview
  • Therapeutics Development
    • Pipeline Products for Coronavirus Infection - Overview
    • Pipeline Products for Coronavirus Infection - Comparative Analysis
  • Coronavirus Infection - Therapeutics under Development by Companies
  • Coronavirus Infection - Therapeutics under Investigation by Universities/Institutes
  • Coronavirus Infection - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Coronavirus Infection - Products under Development by Companies
  • Coronavirus Infection - Products under Investigation by Universities/Institutes
  • Coronavirus Infection - Companies Involved in Therapeutics Development
    • AstraZeneca Plc
    • Hemispherx Biopharma, Inc.
    • Humabs BioMed SA
    • Kineta, Inc.
    • NanoViricides, Inc.
    • Novavax, Inc.
    • Organic Vaccines
    • Phelix Therapeutics, LLC
    • Regeneron Pharmaceuticals, Inc.
  • Coronavirus Infection - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • coronavirus vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • coronavirus vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Drugs to Inhibit Cathepsin L for Infectious Diseases - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • FBR-001 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • interferon alfa-n3 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • interferon beta-1a - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LCA-60 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MERS-CoV Vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Middle East respiratory syndrome vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibodies for Middle East Respiratory Syndrome - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody for Coronavirus Infection - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SAB-301 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule for Middle East Respiratory Syndrome Human Coronavirus Infection - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules for Viral Infections - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Agonize IRF-3 for Viral Infections - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SSYA-10001 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Coronavirus Infection - Recent Pipeline Updates
  • Coronavirus Infection - Dormant Projects
  • Coronavirus Infection - Product Development Milestones
    • Featured News & Press Releases
      • Oct 19, 2015: Hemispherx Biopharma Europe Receives Positive Opinion on Application for Orphan Designation by the European Medicines Agency for Alferon N Injection to Treat Patients with Middle East Respiratory Syndrome
      • Apr 30, 2014: New Experimental Vaccine Produces Immune Response Against Middle East Respiratory Syndrome Coronavirus
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Coronavirus Infection, H1 2016
  • Number of Products under Development for Coronavirus Infection - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Comparative Analysis by Unknown Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016
  • Coronavirus Infection - Pipeline by AstraZeneca Plc, H1 2016
  • Coronavirus Infection - Pipeline by Hemispherx Biopharma, Inc., H1 2016
  • Coronavirus Infection - Pipeline by Humabs BioMed SA, H1 2016
  • Coronavirus Infection - Pipeline by Kineta, Inc., H1 2016
  • Coronavirus Infection - Pipeline by NanoViricides, Inc., H1 2016
  • Coronavirus Infection - Pipeline by Novavax, Inc., H1 2016
  • Coronavirus Infection - Pipeline by Organic Vaccines, H1 2016
  • Coronavirus Infection - Pipeline by Phelix Therapeutics, LLC, H1 2016
  • Coronavirus Infection - Pipeline by Regeneron Pharmaceuticals, Inc., H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Coronavirus Infection Therapeutics - Recent Pipeline Updates, H1 2016
  • Coronavirus Infection - Dormant Projects, H1 2016

List of Figures

  • Number of Products under Development for Coronavirus Infection, H1 2016
  • Number of Products under Development for Coronavirus Infection - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Targets, H1 2016
  • Number of Products by Stage and Targets, H1 2016
  • Number of Products by Mechanism of Actions, H1 2016
  • Number of Products by Stage and Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Types, H1 2016
Back to Top